← Back to Search

Beta Blocker

Carvedilol for Atrial Fibrillation

N/A

Waitlist Available

Led By Anne M Gillis, M.D.

Research Sponsored by University of Calgary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

NYHA Class II or greater CHF

Unable to give informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare the effectiveness of two drugs, carvedilol and metoprolol, in preventing a heart rhythm disorder called atrial fibrillation.

Who is the study for?

This trial is for people with a heart rhythm disorder called paroxysmal atrial fibrillation, who've had symptoms recently. They must be able to consent and not have other serious heart conditions or life-threatening illnesses. It's not for those who can't take beta blockers due to past bad reactions.

What is being tested?

The study compares two drugs, Carvedilol and Metoprolol, to see which one is better at preventing episodes of irregular heartbeat in patients with atrial fibrillation. Participants will be randomly assigned to receive one of the two medications.

What are the potential side effects?

Possible side effects from both Carvedilol and Metoprolol include dizziness, fatigue, low blood pressure, slow heartbeat, and digestive issues. Each person may experience these differently.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have heart failure that affects my daily activities.

Select...

I am unable to understand and agree to the study's details on my own.

Select...

I cannot take Beta blockers due to severe side effects or other medical reasons.

Select...

My atrial fibrillation is caused by a condition that can be treated or reversed.

Select...

I have ongoing atrial fibrillation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Event-free survival to first detected AF after the one month blanking period for dose titration

Secondary study objectives

AF Severity Scale

Adverse effects of assigned therapy

CCS AF Symptom Score

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: MetoprololActive Control1 Intervention

The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.

Group II: CarvedilolActive Control1 Intervention

The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.

0 / 5Eligibility criteria met